Connective Tissue Neoplasm
Background
Connective tissue neoplasms refer to abnormal growths that originate from the body's connective tissues. These tissues are fundamental to the body's structure, providing support, connecting other tissues, and storing fat. They include bone, cartilage, fat, ligaments, tendons, and blood vessels, and are found throughout the body. Neoplasms can range from benign (non-cancerous) growths, which are often localized and do not spread, to malignant (cancerous) tumors, known as sarcomas, which can invade surrounding tissues and metastasize to distant parts of the body. Given the ubiquitous nature and diverse functions of connective tissues, neoplasms arising from them can present in various forms and locations, impacting a wide range of bodily functions.
Biological Basis
The development of connective tissue neoplasms, like many other cancers, is influenced by a complex interplay of genetic and environmental factors. Genetic variations, particularly single nucleotide polymorphisms (SNPs), play a significant role in an individual's susceptibility to developing these conditions. SNPs are common DNA sequence variations that can alter gene function, protein expression, or cellular processes, thereby influencing cellular growth, differentiation, and repair mechanisms.
Genome-wide association studies (GWAS) have been instrumental in identifying specific genetic loci associated with an increased risk for various cancers. These studies systematically scan the entire genome for common genetic variants that are more frequent in individuals with a disease compared to healthy controls. For example, GWAS have revealed multiple susceptibility loci for different types of cancer, often identifying SNPs within or near genes involved in immune response, cell cycle regulation, and other critical pathways. [1] Many significant associations have been found within the Human Leukocyte Antigen (HLA) region on chromosome 6p21.3, which plays a crucial role in immune system function. [2] Specific SNPs, such as rs29232, rs2517713, and rs2975042, located near genes like GABBR1, HLA-A, HLA-F, and HCG9, have been linked to cancer susceptibility. [3] Beyond single SNP associations, research also explores how multiple SNPs can interact to influence disease risk, forming complex interaction patterns. [4] Understanding these genetic underpinnings is crucial for unraveling the molecular mechanisms driving neoplasm development.
Clinical Relevance
Understanding the genetic basis of connective tissue neoplasms has profound clinical relevance. Identifying specific genetic markers or patterns of SNPs can aid in early diagnosis, prognostication, and the development of personalized treatment strategies. For individuals with a genetic predisposition, this knowledge can facilitate targeted screening programs, allowing for earlier detection and intervention. Genetic insights can also guide therapeutic decisions, helping clinicians select treatments that are more likely to be effective for a patient's specific genetic profile, thus moving towards precision medicine. Furthermore, studying these genetic associations helps in classifying tumors more accurately, which can lead to more tailored and effective management plans, potentially improving patient outcomes and reducing treatment-related toxicities.
Social Importance
The social importance of understanding connective tissue neoplasms extends beyond individual patient care to broader public health and societal well-being. These conditions can significantly impact the quality of life for patients and their families, leading to physical, emotional, and financial burdens. Improved genetic understanding can foster public health initiatives focused on risk assessment, prevention, and early detection strategies. It can also inform genetic counseling, helping individuals and families understand their risk and make informed decisions about genetic testing and family planning. Moreover, research into the genetic determinants of neoplasms contributes to a broader scientific understanding of human health and disease, driving innovation in diagnostics and therapeutics that can benefit diverse populations globally.
Methodological and Statistical Power Limitations
Research in genetic associations is frequently constrained by the statistical power inherent in study designs and sample sizes, which can limit the detection of genetic variants with small effect sizes. Current methodologies may only be powered to identify common variants explaining a minor percentage of a trait's variance, leaving many subtle but real effects, particularly those specific to certain age or sex groups, undetected. [5] The challenge of low statistical power is further amplified when attempting to replicate findings, as variants with small effects are easily missed in subsequent studies, contributing to perceived replication gaps. [6] Furthermore, the selection between fixed-effects and random-effects models in meta-analyses can impact the significance of findings, with some markers showing significant heterogeneity and losing genome-wide significance under random-effects models that account for between-study variability. [5]
Beyond sample size, the rigorous quality control applied to genetic data, such as excluding poorly imputed single nucleotide polymorphisms (SNPs) or those with low minor allele frequencies, can inadvertently limit the scope of detectable associations. [7] While crucial for minimizing false positives from multiple hypothesis testing and population stratification, these filters, alongside the use of different genotyping platforms across studies, highlight the need for careful harmonization of data. [5] The current genome-wide association study (GWAS) approach, despite its unbiased nature, typically covers only a subset of all possible SNPs, meaning it may not capture all genes or rare alleles influencing a phenotype due to limited coverage. [5]
Population Heterogeneity and Phenotypic Specificity
The generalizability of genetic findings can be significantly affected by population heterogeneity and the specific definitions of phenotypes under investigation. Population stratification, where differences in allele frequencies between subgroups within a study population can lead to spurious associations, remains an inherent possibility in GWAS despite the application of genomic control and principal component analysis to mitigate its impact. [5] Variations in linkage disequilibrium patterns and allele frequencies across diverse ancestral populations can also hinder the direct replication of findings or limit their applicability to different ethnic groups. [6]
Moreover, the precise definition and measurement of complex traits introduce further limitations. For instance, traits measured at different anatomical sites may have distinct genetic underpinnings, meaning that findings from one site may not directly translate to another. [6] The practice of performing only sex-pooled analyses, while increasing statistical power, risks overlooking SNPs that exhibit associations exclusively in males or females. [8] Such phenotypic nuances and the potential for heterogeneity within broad disease classifications necessitate larger studies with more specific trait categorizations to uncover the full genetic landscape. [9]
Unaccounted Genetic Complexity and Environmental Influences
A substantial portion of the heritability for many complex traits often remains unexplained by identified genetic variants, pointing to significant knowledge gaps. Current GWAS are typically underpowered to detect complex genetic architectures, such as gene-gene (epistatic) or gene-environment interactions, which are likely to play crucial roles in disease etiology and trait variation. [5] The effects of rare alleles, which are not adequately captured by the common variant arrays used in most GWAS, also contribute to this "missing heritability" and represent an important area for future investigation. [5]
The small expected effect sizes of individual genetic variants, coupled with an incomplete understanding of their interactions with environmental factors, contribute to the challenge of fully elucidating the genetic basis of complex traits. [9] This limitation means that many markers with subtle effects may still await discovery, requiring even larger study cohorts to achieve the necessary statistical power. [9] Furthermore, while genetic associations may be identified, determining their direct impact on downstream clinical outcomes, such as disease risk or progression, often requires further dedicated research that extends beyond initial discovery efforts. [5]
Variants
Genetic variations within genes like INTS10, USP20, and LRP1B can influence fundamental cellular processes that, when disrupted, may contribute to the development of connective tissue neoplasms. INTS10 (Integrator Complex Subunit 10) is part of the Integrator complex, which plays a crucial role in RNA polymerase II-mediated transcription termination and processing of small nuclear RNAs. Perturbations in gene expression regulation, as potentially influenced by variants like rs577319126, can lead to uncontrolled cell proliferation or altered cell differentiation, characteristics often seen in various cancers, including those affecting connective tissues. [10] Similarly, USP20 (Ubiquitin Specific Peptidase 20) is a deubiquitinating enzyme that removes ubiquitin tags from proteins, thereby stabilizing them or altering their cellular localization. Variants such as rs368480426 in USP20 could affect protein stability or signaling pathways critical for cell cycle control and apoptosis, potentially promoting aberrant cell survival or growth in connective tissues. [4]
LRP1B (Low-Density Lipoprotein Receptor-Related Protein 1B) is a large receptor protein often implicated as a tumor suppressor gene due to its role in cell adhesion, migration, and signal transduction pathways that regulate cell growth and differentiation. It is known to bind various ligands and can modulate pathways like Wnt signaling, which is frequently dysregulated in cancers. Variants like rs182867289 and rs549928751 within LRP1B could impair its tumor suppressive functions, leading to increased cell proliferation, reduced apoptosis, and enhanced metastatic potential, thereby contributing to the initiation or progression of connective tissue neoplasms. [1] Given its extensive extracellular
Other genes, including LINC01194, C10orf143, THSD7B, ANXA11, and KIF13A, also contribute to cellular health and disease susceptibility. LINC01194 is a long intergenic non-coding RNA (lncRNA) that can regulate gene expression through various mechanisms, including chromatin remodeling and C10orf143 (Chromosome 10 Open Reading Frame 143) encodes a protein whose precise function is still under investigation, but like many uncharacterized proteins, it may play subtle yet significant roles in cellular processes. A variant such as rs117510937 might impact protein function or expression, potentially leading to cellular dysregulation relevant to neoplasm. [11]
THSD7B (Thrombospondin Type 1 Domain Containing 7B) encodes a protein involved in angiogenesis, the formation of new blood vessels, a process critical for tumor growth and metastasis. Alterations in THSD7B due to variants like rs116067048 could influence the vascularization of tumors, affecting their ability to grow and spread in connective tissues. [2] ANXA11 (Annexin A11) is a calcium-dependent phospholipid-binding protein involved in membrane trafficking, exocytosis, and DNA repair. Variants such as rs147037308 could affect these processes, potentially impacting cellular responses to stress or damage, which are relevant to tumor initiation and progression. [12] Finally, KIF13A (Kinesin Family Member 13A) is a motor protein involved in intracellular transport, including the movement of vesicles and organelles. Variants like rs185617584 in KIF13A could disrupt cellular organization or signaling pathways, which are essential for maintaining normal cell function and preventing uncontrolled growth in connective tissues. [13]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs577319126 | INTS10 - LPL | connective tissue neoplasm |
| rs368480426 | USP20 | connective tissue neoplasm |
| rs182867289 | LRP1B | connective tissue neoplasm |
| rs549928751 | LRP1B | connective tissue neoplasm |
| rs140211887 | LINC01194 | connective tissue neoplasm |
| rs117510937 | C10orf143 | connective tissue neoplasm |
| rs116067048 | THSD7B | connective tissue neoplasm |
| rs147037308 | ANXA11 | connective tissue neoplasm |
| rs185617584 | KIF13A | connective tissue neoplasm |
Clinical Characterization and Diagnostic Confirmation
The initial characterization of neoplasms, such as follicular lymphoma and nasopharyngeal carcinoma, involves a thorough review of phenotype information and classification based on established international standards. Cases are centrally reviewed and classified according to schemes like the World Health Organization (WHO) classification. [1] This structured approach ensures consistency in defining the clinical presentation and pathological features of the disease. Diagnostic confirmation relies significantly on objective assessment methods, including biopsies and detailed pathology reports, which are crucial for verifying the diagnosis and guiding subsequent management. [1] Further information on disease stage and treatment is often collected from hospital tumor registries and medical charts, providing a comprehensive understanding of the disease's initial presentation and progression. [3]
Heterogeneity in Disease Presentation and Course
Connective tissue neoplasms can exhibit considerable heterogeneity in their presentation and progression, influenced by various individual and disease-specific factors. Studies indicate variability across patient demographics, with specific cancers showing differing male-to-female ratios and age distributions. [3] For instance, nasopharyngeal carcinoma patient cohorts have been observed with a mean age of 46.3 years, ranging from 10 to 77 years, highlighting a broad age spectrum of presentation. [14] Beyond demographic factors, the clinical course can vary significantly, including instances of resistance to radiotherapy or the development of distal metastasis, which represent severe forms of disease progression and impact prognostic indicators. [4] A family history of the disease can also serve as a critical indicator, suggesting inherited predispositions or shared environmental risk factors. [4]
Molecular and Genetic Assessment
The diagnostic and prognostic understanding of neoplasms is significantly enhanced by molecular and genetic assessment methods. For certain cancers like nasopharyngeal carcinoma, a high percentage of cases, approximately 96.3%, are positive for Epstein-Barr virus (EBV) IgA/VCA antibodies, which can serve as an important diagnostic biomarker. [14] Advanced genetic tools, such as genome-wide association studies (GWAS) and SNP genotyping, are employed to identify genetic markers associated with susceptibility or disease characteristics. [1] High-resolution HLA molecular typing, utilizing techniques like PCR-SSOP and DNA sequence-based typing (SBT), further contributes to a detailed genetic profile, providing insights into potential immunogenetic predispositions and aiding in confirming diagnosis. [14] These objective measurement approaches offer valuable diagnostic value and help in correlating genetic profiles with clinical phenotypes.
Genetic Predisposition and Complex Inheritance
The development of connective tissue neoplasms is significantly influenced by an individual's genetic makeup, often exhibiting a complex inheritance pattern involving multiple genetic variants. Genome-wide association studies (GWAS) have identified several susceptibility loci that contribute to risk. Notably, genetic variants within the major histocompatibility complex (MHC) region on chromosome 6p21.3, including those specifically affecting the HLA class I antigen recognition groove, are considered principal genetic determinants.. [3] These findings suggest that immune system regulation, encoded by HLA genes, plays a critical role in modulating susceptibility to certain neoplasms.
Beyond individual genetic markers, gene-gene interactions represent another layer of genetic complexity in neoplasm susceptibility. Specific interactions between single nucleotide polymorphisms (SNPs) can collectively elevate risk more profoundly than individual variants alone. For example, specific SNP pairs, such as rs2237353 within the CREB5 intron, have been observed to interact, where individuals carrying particular double homozygous genotypes (e.g., AA/GG or CC/AA) demonstrate a substantially higher risk.. [4] These intricate genetic networks highlight the polygenic nature of risk, where multiple interacting genes contribute to the overall predisposition.
Environmental Triggers and Lifestyle Factors
Environmental exposures and lifestyle choices are crucial in the etiology of connective tissue neoplasms, often interacting with an individual's genetic susceptibility. Chronic infections, such as those caused by the Epstein-Barr virus, are recognized as significant environmental risk factors, particularly in populations residing in specific geographic regions.. [14] Furthermore, exposure to certain chemical agents, including organochlorines, has been linked to an increased risk of neoplastic development, suggesting that environmental toxins can act as carcinogens.. [1]
Lifestyle factors, including body mass index (BMI), also contribute to the risk profile for neoplasms. Alterations in BMI can influence metabolic pathways and hormonal regulation, such as those involving leptin and its associated receptor polymorphisms, which may impact cellular growth and differentiation.. [1] While comprehensive individual environmental exposure data are often challenging to collect in large-scale genetic studies, their importance in fully characterizing the interplay between genetic predisposition and external influences on neoplasm development is well-acknowledged.. [3]
Gene-Environment Interplay
The emergence of connective tissue neoplasms is frequently a consequence of complex gene-environment interactions, where an individual's inherent genetic predispositions are modulated by specific environmental triggers. For instance, genetic variants within the HLA region may confer altered immune responses or susceptibility to particular viral infections, which then act as environmental catalysts for neoplastic transformation.. [3] This interplay underscores how genetic risk factors might be either attenuated or exacerbated by varying environmental exposures, making it essential to consider both components in risk assessment.
Understanding these intricate interactions is critical for a comprehensive view of neoplasm development, as the effects of genetic associations can be significantly influenced by the presence or absence of key environmental risk factors. Studies that integrate detailed individual environmental exposure data with genetic information are crucial for elucidating the mechanisms by which genetic and environmental factors collaboratively contribute to the overall susceptibility and progression of connective tissue neoplasms.. [3]
Biological Background
The provided research studies primarily focus on Nasopharyngeal Carcinoma (NPC) and Follicular Lymphoma, which are not classified as connective tissue neoplasms. Consequently, a biological background section specifically for 'connective tissue neoplasm' cannot be constructed based on the information given.
Dysregulated Signal Transduction and Transcriptional Control
The development of connective tissue neoplasms often involves the aberrant activation or suppression of critical signaling pathways that govern cell growth, differentiation, and survival. For instance, the identification of novel tyrosine kinases highlights their potential involvement in intracellular signaling cascades that, when dysregulated, can contribute to uncontrolled proliferation. [15] Key inflammatory and survival pathways, such as the NF-κB pathway, are frequently implicated, with components like NFKBIK and RELA showing associations that underpin complex regulatory mechanisms. Sustained activation of NF-κB promotes neoplastic progression by enhancing cell survival and inhibiting apoptosis, creating a favorable environment for tumor growth. [16]
Furthermore, the MAPK3 (ERK1) pathway, a central component of the mitogen-activated protein kinase cascade, is crucial for transmitting extracellular signals into the cell nucleus, influencing gene expression and cellular responses. Aberrant activity within this network, such as the ESR1 and MAPK3 network, can lead to uncontrolled cellular proliferation and altered differentiation, contributing to oncogenesis. [17] Similarly, the Wnt signaling pathway, essential for embryonic development and adult tissue homeostasis, becomes aberrantly activated in many cancers. This can occur through the transcriptional silencing of antagonists like DKK1 via promoter methylation, which enhances Wnt signaling and drives neoplastic cell proliferation. [18] Interleukin-21 (IL21) is also recognized as a modulator of immunity and cancer, suggesting its receptor activation and downstream signaling play a role in shaping the tumor microenvironment and influencing cancer cell behavior. [19]
Genomic Integrity and Epigenetic Reprogramming
Maintaining genomic integrity is a fundamental requirement for preventing neoplastic transformation, and dysfunctions in DNA repair mechanisms can significantly increase cancer susceptibility by allowing mutations to accumulate. [10] Beyond direct genetic mutations, epigenetic alterations, particularly DNA methylation, profoundly influence gene expression patterns without altering the DNA sequence itself. A notable example is the promoter methylation of the Wnt-antagonist DKK1, which leads to its transcriptional silencing and consequently enhances Wnt signaling, driving cell proliferation in various cancers, including those affecting connective tissues. [18]
The precise regulation of gene expression is also controlled by complex interactions between genes and distant regulatory elements. For instance, the oncogene MYC, a master transcription factor controlling cell growth and division, is subject to regulation by long-range enhancers. These enhancers, located far from the MYC gene on chromosomes such as 8q24, interact with the gene's promoter to fine-tune its expression in a tissue-specific manner. Dysregulation of these long-range interactions can lead to aberrant MYC overexpression, contributing significantly to the pathogenesis of various cancers by altering transcriptional programs that promote cell proliferation and survival. [20]
Altered Cellular Architecture and Extracellular Matrix Dynamics
The structural and dynamic properties of cells, including their ability to move and divide, are profoundly altered in connective tissue neoplasms. Proteins like WBSCR17 play a role in regulating lamellipodium formation and macropinocytosis, processes critical for cell migration, invasion, and nutrient uptake—mechanisms vital for tumor growth and metastasis. [21] Furthermore, precise and controlled cell division is essential for normal tissue development, involving intricate machinery like centriolin, which anchors exocyst and SNARE complexes at the midbody to facilitate secretory-vesicle-mediated abscission. Dysregulation of these components can lead to abnormal cytokinesis and uncontrolled proliferation, a defining characteristic of neoplastic cells. [22]
The extracellular matrix (ECM) provides crucial structural support and biochemical cues that regulate cell behavior within connective tissues. Proteins such as SMOC-1, a modular calcium-binding protein found in basement membranes, are important components of this intricate network. SMOC1 is also recognized as an important ECM protein involved in osteoblast differentiation, highlighting its role in the organization and maintenance of connective tissues. [23] In neoplastic conditions, alterations in the composition and remodeling of the ECM can significantly impact tumor progression, facilitating invasion and metastasis by modifying cell-matrix interactions and creating a microenvironment conducive to cancer cell survival and spread.
Interconnected Pathway Networks and Disease Relevance
The pathogenesis of connective tissue neoplasms is rarely driven by a single pathway but rather by the intricate crosstalk and network interactions of multiple dysregulated mechanisms, leading to emergent properties characteristic of cancer. For instance, the enhanced Wnt signaling resulting from DKK1 promoter methylation does not operate in isolation but can interact with and amplify signals from other pro-survival pathways, collectively promoting uncontrolled cellular expansion. [18] Similarly, the NF-κB pathway, orchestrated by components like NFKBIK and RELA, integrates inflammatory and cellular stress signals, creating a robust pro-tumorigenic environment that supports cell survival, proliferation, and resistance to therapy. [16]
Understanding these interconnected pathway networks is crucial for identifying disease-relevant mechanisms and developing effective therapeutic strategies. The role of MAPK3 in cell growth and the broader influence of IL21 as a modulator in cancer highlight potential targets for intervention. [17] By elucidating how oncogenes like MYC are aberrantly activated through long-range enhancer interactions, researchers can identify novel vulnerabilities. [20] These systems-level insights into pathway dysregulation, feedback loops, and compensatory mechanisms offer promising avenues for developing targeted therapies that precisely disrupt the molecular underpinnings of connective tissue neoplasia.
Frequently Asked Questions About Connective Tissue Neoplasm
These questions address the most important and specific aspects of connective tissue neoplasm based on current genetic research.
1. My parent had a tumor; am I more likely to get one?
Yes, there's a possibility. Your risk can be influenced by genetic variations you inherit, especially if those variations are linked to an increased susceptibility to tumors. These genetic factors, often common DNA sequence variations, play a significant role in determining who develops these conditions.
2. If tumors run in my family, should I get special screenings?
Yes, understanding your family history and potential genetic predisposition can be very valuable. This knowledge can help guide your doctors to consider targeted screening programs, which allow for earlier detection and intervention if a tumor were to develop. It's a key part of personalized care.
3. Why might a tumor treatment work differently for me than for someone else?
Treatment effectiveness can vary because your unique genetic profile influences how your body responds. Specific genetic markers or patterns of variations can guide doctors in selecting treatments that are more likely to be effective for you, moving towards what's called precision medicine. This helps tailor therapies for better outcomes.
4. Does my ethnic background change my tumor risk?
Yes, your ethnic background can influence your genetic risk. Differences in genetic patterns and how genes are linked (linkage disequilibrium) vary across different populations. While studies try to account for this, population differences mean that genetic findings can be more relevant to certain groups.
5. What do genetics mean for how my tumor is classified?
Genetics are crucial for accurate tumor classification. Identifying specific genetic markers helps doctors understand the molecular mechanisms driving your tumor's development. This detailed genetic insight can lead to a more precise diagnosis and a more tailored and effective management plan for you.
6. What can I do if I know I have a higher genetic risk?
If you have a higher genetic risk, this knowledge allows for proactive steps. It can facilitate targeted screening and early detection, which are key for better outcomes. Genetic insights also inform genetic counseling, helping you understand your risk and make informed decisions about your health.
7. Is genetic testing useful to understand my tumor risk?
Yes, genetic testing can be very useful. Identifying specific genetic markers or patterns of variations through approaches like genome-wide association studies can help assess your individual susceptibility. This information can aid in early diagnosis and help guide personalized health strategies.
8. Why do some people get these tumors, but others don't?
It's a complex interplay of your unique genetic makeup and environmental factors. Even with similar lifestyles, individuals have different genetic variations, like single nucleotide polymorphisms (SNPs), that can influence their susceptibility. These variations affect cellular growth and repair mechanisms, leading to different outcomes.
9. If I have a tumor, should I worry about my future children?
It's a valid concern, and genetics can play a role. Your genetic predisposition could be passed on, influencing your children's susceptibility. Genetic counseling can provide important information, helping you understand potential risks and make informed decisions regarding family planning.
10. Can my daily habits really outweigh my genetic predisposition?
While genetics play a significant role in susceptibility, the development of tumors is influenced by a complex interplay of both genetic and environmental factors. Managing environmental influences alongside understanding your genetic profile is important for overall health, even though the specific daily habits aren't fully detailed for these tumors.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Skibola CF, et al. "Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region." Am J Hum Genet, 2014.
[2] Skibola CF. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. PMID: 19620980
[3] Tse KP, et al. "Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3." Am J Hum Genet, 2009.
[4] Su WH. How genome-wide SNP-SNP interactions relate to nasopharyngeal carcinoma susceptibility. PLoS One. PMID: 24376627
[5] Rivadeneira F, et al. "Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies." Nat Genet, 2009.
[6] Guo Y, et al. "IL21R and PTH may underlie variation of femoral neck bone mineral density as revealed by a genome-wide association study." J Bone Miner Res, 2009.
[7] Estrada K, et al. "Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture." Nat Genet, 2012.
[8] Yang Q, et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, 2007.
[9] De Vivo I, et al. "Genome-wide association study of endometrial cancer in E2C2." Hum Genet, 2014.
[10] McKay JD. A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet. PMID: 21437268
[11] Conde L. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. PMID: 20639881
[12] Smedby KE. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. PMID: 21533074
[13] Kung AW. Association of JAG1 with bone mineral density and osteoporotic fractures: a genome-wide association study and follow-up replication studies. Am J Hum Genet. PMID: 20096396
[14] Tang, M. "The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove." PLoS Genet, vol. 8, no. 12, 2012, p. e1003108.
[15] Bennett, B. D. et al. "Identification and characterization of a novel tyrosine kinase from megakaryocytes." J Biol Chem, vol. 269, no. 14, 1994, pp. 1068–1074.
[16] Pare, G. et al. "Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci." PLoS Genet, vol. 7, no. 5, 2011, e1001374.
[17] Xiao, P. et al. "In vivo genome-wide expression study on human circulating B cells suggests a novel ESR1 and MAPK3 network for postmenopausal osteoporosis." J Bone Miner Res, vol. 23, no. 5, 2008, pp. 644–654.
[18] Moayyeri, A. et al. "Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium." Hum Mol Genet, vol. 23, no. 12, 2014, pp. 3013–3022.
[19] Brandt, K. et al. "Interleukin-21: a new modulator of immunity, infection, and cancer." Cytokine Growth Factor Rev, vol. 18, no. 3-4, 2007, pp. 223–232.
[20] Ahmadiyeh, N. et al. "8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC." Proc Natl Acad Sci U S A, vol. 107, no. 21, 2010, pp. 9742–9746.
[21] Nakayama, Y. et al. "A putative polypeptide N-acetylgalactosaminyltransferase/Williams-Beuren syndrome chromosome region 17 (WBSCR17) regulates lamellipodium formation and macropinocytosis." J Biol Chem, vol. 287, no. 38, 2012, pp. 32222–32235.
[22] Gromley, A. et al. "Centriolin anchoring of exocyst and SNARE complexes at the midbody is required for secretory-vesicle-mediated abscission." Cell, vol. 123, no. 1, 2005, pp. 75–87.
[23] Vannahme, C. et al. "Characterization of SMOC-1, a novel modular calcium-binding protein in basement membranes." J Biol Chem, vol. 277, no. 40, 2002, pp. 37977–37986.